Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Frequently asked questions
What sector does Eikon Therapeutics, Inc. Common Stock (EIKN) operate in?
Eikon Therapeutics, Inc. Common Stock belongs to the Other sector and operates in the Biotechnology industry.
What is Eikon Therapeutics, Inc. Common Stock (EIKN) current stock price?
As of the latest data, Eikon Therapeutics, Inc. Common Stock stock price is $9.44, with a previous close of $9.21. Eikon Therapeutics, Inc. Common Stock gained $0.23 in the last trading session, representing a 2.44% increase.
What is Eikon Therapeutics, Inc. Common Stock (EIKN) current market capitalization?
Eikon Therapeutics, Inc. Common Stock market cap is approximately 510.80 million.
What is Eikon Therapeutics, Inc. Common Stock (EIKN) Earnings Per Share (EPS)?
The trailing EPS is -$6.32, and the forward EPS is -$6.19.
What is Eikon Therapeutics, Inc. Common Stock (EIKN) EBITDA?
Eikon Therapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -77.84 million.
Does Eikon Therapeutics, Inc. Common Stock (EIKN) pay dividends?
No. Eikon Therapeutics, Inc. Common Stock does not pay a dividend.
When is Eikon Therapeutics, Inc. Common Stock (EIKN) next earnings report?
Eikon Therapeutics, Inc. Common Stock is expected to release its next earnings report on June 30, 2026.
What is Eikon Therapeutics, Inc. Common Stock (EIKN) beta (volatility) score?
Eikon Therapeutics, Inc. Common Stock has a beta of 0.082, indicating lower volatility than the overall market.
